Biobanking - Evaluating the Benefits of Public-Private Partnerships
Add bookmark
In this interview Heli Salimen-Mankonen, Research Director, Auria Biobank, speaks to Andrea Charles from Pharma IQ about forming and sustaining public-private partnerships and the evaluating the benefits of this collaboration.
Pharma IQ: What are the key differences between the sectors?
H Salimen-Mankonen: Human biological samples and medical data are provided as donations and are considered as common goods, while the private industry sector needs access to biospecimen and data to de...
